Form 4: RIGL EVP Granted 18,894 Shares via RSU Award

Rigel Pharmaceuticals' EVP, Chief Medical Officer Lisa Rojkjaer, was granted 18,894 shares of common stock through a Restricted Stock Unit award.

Summary

• Lisa Rojkjaer, EVP, Chief Medical Officer of Rigel Pharmaceuticals Inc. (RIGL), was granted 18,894 shares of common stock.
• These shares are to be acquired upon the vesting of a Restricted Stock Unit (RSU) award.
• The RSU award will vest quarterly over three years, with the first quarterly vest scheduled for March 31, 2026.
• Following this reported transaction, Lisa Rojkjaer beneficially owns 34,853 shares of common stock.
• The transaction date for the RSU grant was February 17, 2026, with a price of $0 per share for the acquisition.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a slightly positive development, as it represents a standard executive compensation practice that aligns management's interests with shareholders through increased insider ownership.

Positives

• The grant of Restricted Stock Units (RSUs) to a key executive, Lisa Rojkjaer, aligns her interests with those of shareholders, incentivizing long-term performance.
• Increased insider ownership can signal confidence in the company's future prospects.

Negatives

• No direct negatives are apparent from this routine insider compensation filing.

Risks

• The value of the RSU award is tied to the future stock price of Rigel Pharmaceuticals, Inc., meaning the actual value realized by the executive could be lower if the stock price declines.
• Future dilution from RSU vesting is a minor consideration for existing shareholders, though this is a standard compensation practice.

Future Outlook

The vesting schedule of the RSU award indicates that Lisa Rojkjaer will acquire beneficial ownership of the granted shares quarterly over the next three years, starting March 31, 2026, contingent on continued employment and company performance as per the RSU terms.

Industry Context

StockSavvy.ai notes that the granting of Restricted Stock Units (RSUs) to executive officers is a common and widely accepted practice in the biotechnology and pharmaceutical industries. This compensation structure is designed to attract and retain top talent while aligning executive incentives with long-term shareholder value creation. Many companies, including peers of Rigel Pharmaceuticals, utilize RSUs as a significant component of their executive compensation packages.

Comparison to Industry Standards

• The RSU grant to Lisa Rojkjaer is consistent with standard executive compensation practices observed across the biotechnology and pharmaceutical sectors.
• Companies like Amgen (AMGN), Gilead Sciences (GILD), and Biogen (BIIB) frequently use RSU awards as a key component of their executive incentive programs, typically with multi-year vesting schedules to promote long-term commitment and performance.
• The vesting schedule of quarterly over three years is a common structure, similar to those seen in grants at companies such as Moderna (MRNA) or Pfizer (PFE) for their senior executives, aiming to retain talent and link compensation to sustained company performance.

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of executive interests with long-term shareholder value; minor potential for future dilution from vesting shares.
• Employees: May signal stability and a commitment to executive retention, potentially boosting morale.

Next Steps

• The Restricted Stock Units will vest quarterly over three years, with the first vest occurring on March 31, 2026.

Key Dates

Keywords

Rigel Pharmaceuticals, RIGL, Form 4, Insider Transaction, Restricted Stock Unit, RSU, Executive Compensation, Lisa Rojkjaer, Common Stock, Beneficial Ownership